SCHEMBL19976722

SCHEMBL19976722

CC(C)c1[nH]nc2cnccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA1 Q13131 2/20 0.37
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAG3 Q9UGI9 1/20 0.37
PRKAG2 Q9UGJ0 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
KDM4C Q9H3R0 4/20 0.36
KDM4A O75164 2/20 0.36
KDM5C P41229 2/20 0.36
KDM4B O94953 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
LATS1 O95835 11/20 0.36
LATS2 Q9NRM7 9/20 0.36
PIM1 P11309 3/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KDM4D Q6B0I6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25952897 0.85 PRKAA1 (0.37) PRKAA1PRKAB2PRKAG1PRKAA2PRKAG3
SCHEMBL18556889 0.80 KDM4C (0.38) KDM4CLATS1LATS2KDM4E
SCHEMBL15233164 0.75 PIM1 (0.51) PRKAA1KDM4CKDM4AKDM5CKDM4B
SCHEMBL6842156 0.75 CYP1A2 (0.50) KDM4EAURKAAURKB
SCHEMBL2375092 0.71 KDM4C (0.39) PRKAA1KDM4CKDM4AKDM5CKDM4B
SCHEMBL13122880 0.70 CHEK1 (0.39) PIM1KDM4ECHEK1RPS6KA3
SCHEMBL21299800 0.70 LATS1 (0.41) PRKAA1KDM4CKDM4AKDM5CKDM4B
SCHEMBL15935235 0.70 LATS1 (0.36) PRKAA1KDM4CKDM4AKDM5CKDM4B
SCHEMBL13122014 0.70 KIF11 (0.40) KDM4EKDRAURKADAPK3JAK2
SCHEMBL2750543 0.67 CCNB2 (0.39) PIM1CDK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor JAPAN TOBACCO INC. (JP) 2023-12-14 US disclosed
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor JAPAN TOBACCO INC. (JP) 2023-12-14 US disclosed
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor NLRP3, NLRP1, NOD1 PRKAA1 1485/4885PRKAB2 3513/4885PRKAG1 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.